Vnitr Lek 2014, 60(12):1076-1080
Do natriuretic peptides have a new chance in treatment of heart failure?
- 1 I. interní kardio-angiologická klinika LF MU a FN u sv. Anny Brno, přednostka prof. MUDr. Lenka ©pinarová, Ph.D., FESC
- 2 Interní kardiologická klinika LF MU a FN Brno, pracoviątě Bohunice, přednosta prof. MUDr. Jindřich ©pinar, CSc., FESC
The effect of natriuretic peptides on cardiovascular and renal system offers a potential benefit in therapy of hypertension and heart failure; however the current results of clinical trials are not encouraging. Synthetic B natriuretic peptide has demonstrated short-term hemodynamic improvement in patients, but in terms of renal function and long-term prognosis the effect was questionable. Nevertheless, new hope is ularitid a dual inhibitor of neprilysin and ARB: LCZ 696, the ongoing clinical studies and previous data from pilot studies appear promising.
Keywords: heart failure; natriuretic peptides; vasopeptidase inhibitors
Received: July 17, 2014; Accepted: August 15, 2014; Published: December 1, 2014 Show citation
References
- Mills RM, LeJemtel TH, Horton DP et al. Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure. A randomized, double-blind, placebo-controlled clinical trial. NATRECOR Study Group. J Am Coll Cardiol 1999; 34(1): 155-162.
Go to original source... 
Go to PubMed... - Colluci WS, Elkayem U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. NESIRITIDE Study Group. N Engl J Med 2000; 343(4): 246-253. Errata in N Engl J Med 2000 Nov 16; 343(20): 1504 et N Engl J Med 2000; 343(12): 896. Go to original source... Go to PubMed...
- The VMAC Investigators. Intravenous neseritide vs nitroglycerin for treatment of decompesated congestive heart failure. JAMA 2002; 287(12): 1531-1540. Erratum in JAMA 2002; 288(5): 577. Go to original source... Go to PubMed...
- Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111(12): 1487-1491. Erratum in Circulation 2005; 111(17): 2274. Go to original source... Go to PubMed...
- O'Connor CM, Starling RC, Hernandez AF et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365(1): 32-43. Erratum in N Engl J Med. 2011; 365(8): 773. Go to original source... Go to PubMed...
- Chen HH, Anstrom KJ, Givertz MM et al. Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction. The ROSE Acute Heart Failure Randomized Trial. JAMA 2013; 310(23): 2533-2543. Go to original source... Go to PubMed...
- Mitrovic V, Seferovic PM, Simeunovic D et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006; 27(23): 2823-2832. Go to original source... Go to PubMed...
- Clinicaltrials.gov. Dostupné z WWW: <http://www.clinicaltrials.gov/ct2/show/NCT01035255>.
- Kostis JB, Packer M, Black HR et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17(2): 103-111. Go to original source... Go to PubMed...
- Packer M, Califf RM, Konstam MA et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106(8): 920-926. Go to original source... Go to PubMed...
- Gu J, Noe A, Chandra P et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual acting angiotensin receptor - neprilysin inhibitor (ARNi). J Clin Pharmacol 2010; 50(4): 401-414. Go to original source... Go to PubMed...
- Salomon SD, Zile M, Pieske B et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 308(9851): 1387-1395. Go to original source... Go to PubMed...
- McMurray JJ, Packer M, Desai AS et al. PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013; 15(9): 1062-1073. Go to original source... Go to PubMed...